Author(s): Alessandra Tedeschi, Jan Burger, Paul M. Barr, et. al. EHA Library. Tedeschi A. Jun 14, 2019; 267308; S107 Session topic: 6. Chronic lymphocytic leukemia and related disorders – Clinical Abstract: S107 Background Ibrutinib (ibr), a first-in-class, once-daily inhibitor of Bruton tyrosine kinase (BTK), is approved in the EU and other regions...
Pro zobrazení tohoto obsahu je třeba být přihlášen.